Cancer Detection via Enzymatic Microassays

通过酶微分析检测癌症

• 批准号: 6692393
• 负责人: BRIAN J SULLIVAN
• 金额: $ 10.66万
• 依托单位: KUMETRIX, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2003-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6692393
• 关键词: biomarker; computer simulation; diagnosis design /evaluation; diffusion; electrochemistry; enzyme activity; microprocessor /microchip; neoplasm /cancer diagnosis; prostate neoplasms; protein tyrosine phosphatase; silicon

DESCRIPTION (provided by applicant): New methods for easy, rapid enzymatic assays in very small sample volumes (sub-microliter) will greatly benefit the prognosis, diagnosis and detection of cancer. The goal of Phase I is to demonstrate the feasibility of adapting silicon microsampling and assay devices originally developed for blood glucose monitoring, to enzyme activity measurement using a novel technique, "Diffusive Enzyme Activity Measurement." An electrochemical redox-mediated prostatic acid phosphatase (PAP) assay will be the example, requiring no on-chip biologicals (providing a potentially long shelf-life). Silicon microchips with the novel diffusional microfluidics will be designed and fabricated. A computer simulation model will be used in the development of the assay. The enzyme chosen for Phase I is a known cancer marker for prostate cancer. Potential commercial applications include enzyme activity measurements on sub-microliter liquid samples, such as blood drawn from experimental animals (or humans), tissue extract specimens, purified enzymes and drug discovery research and development.

描述（由申请人提供）：在非常小的样品体积（亚微升）中进行简单、快速的酶测定的新方法将极大地有利于癌症的预后、诊断和检测。第一阶段的目标是证明将最初为血糖监测而开发的硅微取样和测定设备应用于使用新技术“扩散酶活性测量”的酶活性测量的可行性。“电化学氧化还原介导的前列腺酸性磷酸酶（PAP）测定将是一个例子，不需要芯片上的生物制剂（提供潜在的长保质期）。将设计和制造具有新型扩散微流体的硅微芯片。在试验开发中将使用计算机模拟模型。选择用于I期的酶是前列腺癌的已知癌症标志物。潜在的商业应用包括对亚微升液体样品的酶活性测量，例如从实验动物（或人类）抽取的血液、组织提取物标本、纯化的酶和药物发现研究和开发。